Stryker Co. (NYSE:SYK) Shares Purchased by Clearstead Trust LLC

Clearstead Trust LLC increased its holdings in shares of Stryker Co. (NYSE:SYK) by 5.1% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 13,645 shares of the medical technology company’s stock after purchasing an additional 663 shares during the quarter. Stryker accounts for about 1.1% of Clearstead Trust LLC’s investment portfolio, making the stock its 18th largest holding. Clearstead Trust LLC’s holdings in Stryker were worth $4,913,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Copperwynd Financial LLC increased its position in Stryker by 3.5% during the 4th quarter. Copperwynd Financial LLC now owns 2,362 shares of the medical technology company’s stock worth $851,000 after purchasing an additional 79 shares in the last quarter. Picton Mahoney Asset Management grew its position in Stryker by 12.1% in the fourth quarter. Picton Mahoney Asset Management now owns 762 shares of the medical technology company’s stock valued at $275,000 after acquiring an additional 82 shares in the last quarter. Associated Banc Corp grew its position in Stryker by 1.4% in the fourth quarter. Associated Banc Corp now owns 20,894 shares of the medical technology company’s stock valued at $7,523,000 after acquiring an additional 290 shares in the last quarter. HMV Wealth Advisors LLC acquired a new stake in Stryker in the fourth quarter valued at approximately $841,000. Finally, Ironwood Investment Counsel LLC grew its position in Stryker by 0.9% in the fourth quarter. Ironwood Investment Counsel LLC now owns 3,323 shares of the medical technology company’s stock valued at $1,196,000 after acquiring an additional 30 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Analyst Ratings Changes

Several analysts have issued reports on SYK shares. Barclays increased their price objective on shares of Stryker from $418.00 to $443.00 and gave the company an “overweight” rating in a research report on Monday, February 10th. Wells Fargo & Company increased their price objective on shares of Stryker from $427.00 to $435.00 and gave the company an “overweight” rating in a research report on Wednesday, January 29th. Royal Bank of Canada increased their price objective on shares of Stryker from $425.00 to $435.00 and gave the company an “outperform” rating in a research report on Wednesday, January 29th. Stifel Nicolaus increased their price objective on shares of Stryker from $400.00 to $440.00 and gave the company a “buy” rating in a research report on Wednesday, January 29th. Finally, Citigroup reiterated a “buy” rating and set a $450.00 target price on shares of Stryker in a research note on Wednesday, February 26th. Five equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $421.90.

Insider Buying and Selling at Stryker

In related news, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the sale, the director now directly owns 3,642,075 shares in the company, valued at $1,428,567,498. The trade was a 5.24 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Allan C. Golston sold 2,458 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the transaction, the director now owns 14,895 shares of the company’s stock, valued at $5,705,827.65. This represents a 14.16 % decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by company insiders.

Stryker Stock Performance

Shares of SYK opened at $369.96 on Friday. The business’s fifty day moving average price is $383.04 and its 200 day moving average price is $373.37. Stryker Co. has a 12-month low of $314.93 and a 12-month high of $406.19. The stock has a market capitalization of $141.17 billion, a PE ratio of 47.68, a price-to-earnings-growth ratio of 2.93 and a beta of 0.95. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32.

Stryker (NYSE:SYK) last posted its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period in the previous year, the business earned $3.46 EPS. Equities research analysts forecast that Stryker Co. will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 0.91%. The ex-dividend date is Monday, March 31st. Stryker’s payout ratio is 43.30%.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.